Dotlab is a Rosenman Founders Pledge company.
DotLab has secured $10 million in Series A funding that will be used to drive the development of DotEndo, its proprietary noninvasive diagnostic test for endometriosis.
“The revolutionary technology behind DotLab’s endometriosis test could improve the lives of the hundreds of millions of women affected by this debilitating disease which has been under-researched and deprioritized for too long,” Heather Bowerman, CEO of DotLab, a healthcare technology company focused on personalized medicine for women’s health, said in a press release.
The financing was led by CooperSurgical, one of the two business units of The Cooper Companies, with individual investors from Tiger Global Management and Luxor Capital Group, as well as from the law firm Wilson Sonsini Goodrich & Rosati.
“CooperSurgical brings significant operational resources and the opportunity to build upon partnerships with health systems to become a leading brand in women’s health,” Bowerman said. “Our shared goal is to make DotLab’s endometriosis test widely accessible.”